BRCA2 germline pathogenic in mCRPC: largest PARPi benefit in HRR pathway (PROfound Cohort...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BRCA2-GERMLINE-PROSTATE |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-PROSTATE |
| Sources | SRC-CIVIC SRC-EAU-PROSTATE-2024 SRC-ESMO-PROSTATE-2024 SRC-NCCN-PROSTATE-2025 |
Actionability Facts
| Biomarker | BIO-BRCA1-BRCA2-GERMLINE |
|---|---|
| Variant | BRCA2 germline pathogenic |
| Disease | DIS-PROSTATE |
| ESCAT tier | IA |
| Recommended combinations | olaparib monotherapy (post-NHA), olaparib + abiraterone (1L), niraparib + abiraterone (1L), talazoparib + enzalutamide (1L), rucaparib monotherapy |
| Evidence summary | BRCA2 germline pathogenic in mCRPC: largest PARPi benefit in HRR pathway (PROfound Cohort A); olaparib post-NHA, 1L olaparib+abiraterone (PROpel), niraparib+abiraterone (MAGNITUDE), talazoparib+enzalutamide (TALAPRO-2) all approved. ESCAT IA / OncoKB Level 1. |
Notes
BRCA2 carriers face aggressive disease phenotype (worse OS untreated). Cascade testing mandatory.
Used By
No reverse references found in the YAML corpus.